Eli Lilly signed a research and collaboration agreement with QurCan Therapeutics to develop therapies for central and peripheral nervous system diseases. The deal is reported at $237 million, positioning QurCan’s platform for CNS drug discovery within Lilly’s broader neuroscience pipeline. The agreement signals continued competition to build CNS capabilities around specialized biology and target discovery, particularly as conventional approaches have delivered mixed results across neurodegenerative and neuropsychiatric indications. For Lilly, the partnership adds to its programmatic effort to deepen CNS-focused modalities, including follow-on work tied to its GIP/GLP-1 neuroscience exploration.